Celsion Breast Cancer Device Trials In Progress: Preliminary Data Favorable
This article was originally published in The Gray Sheet
Executive Summary
Celsion plans to submit a PMA application for the Microfocus APA1000 (adaptive phased array) early-stage primary breast cancer treatment by the second half of 2004
You may also be interested in...
Boston Scientific Microwave BPH Pact Follows Tech Investment Strategy
Boston Scientific's equity investment in microwave benign prostatic hyperplasia (BPH) therapy developer Celsion, including worldwide distribution rights, could lead to an outright purchase of the technology
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.